CRISPR Therapeutics (CRSP) reported Tuesday a Q4 loss of $0.44 per diluted share, swinging from earnings of $1.10 a year earlier.
Analysts polled by FactSet expected a loss of $1.20.
Total revenue for the quarter ended Dec. 31 was $35.7 million, down from 201.2 million a year earlier.
Analysts surveyed by FactSet expected $8.1 million.
As of Dec. 31, the company had about $1.90 billion in cash, cash equivalents, and marketable securities, compared with about $1.7 billion a year earlier.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。